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Available online 28 June 2018Schizophrenia and schizoaffective disorder are chronic and debilitating psychiatric disorders. The present study
was designed to determine DNAdamage in patientswith schizophrenia and schizoaffective disorder to assess the
roles of oxidativemetabolism andDNA repairmechanisms in this process, to assess the contribution of drugs, and
thus to demonstrate the differences between schizophrenia and schizoaffective disorder. Thirty schizophrenia
and 30 schizoaffective disorder patients, each having at least five years of disease history, aged between 18
and 60 years with no physical or neurological diseases, and 30 healthy volunteers participated in the study. Psy-
chometric scaleswere applied, and 5ml of bloodwas taken from all participants. TheDNA damagewasmeasured
in lymphocytes by the comet assay method; the total oxidative parameters by ELISA; OGG1 and NEIL1 gene ex-
pressions by real-time PCR; and the role of drugs by in vitro assays. Themost important finding in this study was
that patientswith schizophrenia had significantly greaterDNAdamage than schizoaffective disorder patients and
the controls. This study also provides evidence of high oxidative stress statuses and inadequate DNA repair capac-
ities in patients with schizophrenia. Moreover, psychotropic drugs did not induce any DNA damage to the lym-
phocytes according to in vitro analyses. The use of clozapine and adequate repair processes of the patients
were the decisive factors in the prevention of DNA damage. The results of this study provide a reexamination
of schizoaffective disorder within the schizophrenia spectrum and indicate that schizoaffective disorder may
be considered a different diagnostic category.
© 2018 Elsevier B.V. All rights reserved.Keywords:
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DNA repair1. Introduction
Schizophrenia and schizoaffective disorder are chronic and dis-
abling psychiatric disorders, the etiologies of which continue to be
confounding and elusive (Soygur et al., 2007). Neurodegenerative
and neurodevelopmental factors have been implicated in the etiolo-
gies of both conditions, but these disorders are frequently consid-
ered together in studies. As a result, very little is known about the
etiological factors specific to schizoaffective disorder (Kaplan and
Sadock, 2004; Malhi et al., 2008). One of the recent intriguing fields
is genetics.
Genotoxicity, a term that describes mutations that cause structural
changes in deoxyribonucleic acid (DNA) or that break the helix ofpartment of Psychiatry, Kınıklı
Topak).
try, Kınıklı Campus, Pamukkale,
dical Biology, Kınıklı Campus,DNA (Kent, 1998), may act as a predisposing factor for both schizophre-
nia and schizoaffective disorder. Reactive oxygen species cause oxida-
tive DNA damage, react with cell membrane proteins, and prevent the
intake of enzymes or neurotransmitters involved in natural processes
(Dizdaroglu, 1999; Gergeroglu et al., 2007). The use of comet assays in
clinical trials has shown increased DNA damage related to many dis-
eases, such as breast cancer (Rajeswari et al., 2000) andAlzheimer's dis-
ease (Migliore et al., 2005), and contributed significantly to the research
efforts to explain the pathogenic mechanisms of these diseases. DNA
damage has also been revealed in psychiatric patient groups by the
use of comet analyses. In the study by Andreazza et al. (2007), outpa-
tients with bipolar disorder were shown to have more DNA damage
than controls, and this damagewas related to the severity of the disease
symptoms. DNA damage has also been observed in schizophrenia pa-
tients (Muraleedharan et al., 2015; Psimadas et al., 2004). This knowl-
edge revealed the need to study DNA damage processes.
Studies evaluating DNA damage have mostly focused on oxidative
processes. In the evaluation of DNA damage, the repair mechanisms
that cells can develop to repair such damage and maintain their geno-
mic integrity must be considered, as well as the oxidative processes.
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sions that cause oxidative damage, is a biomarker for oxidative DNA
damage and is repaired by the enzyme OGG1 (8-oxoguanine DNA
glycosylase) (Boiteux and Radicella, 1999). Polymorphisms in genes
that are involved in DNA repair, including PARP1, OGG1, NEIL1, APE1,
XRCC1, XRCC2, and XRCC3, can change protein function and activity
and the DNA repair capacity of individuals. A lack of repair capacity is
also a major cause of genetic instability (Ekmekci et al., 2008).
Another point that needs to be considered in the evaluation of
DNA damage is the effects of drugs. According to the findings of
Muraleedharan et al. (2015), the significant baseline DNA damage
in schizophrenia, even prior to the initiation of antipsychotic treat-
ment, is very important. Even so, the positive or negative influence
of drugs on DNA damage cannot be disregarded and should be in-
cluded in the evaluation.
The aims of this study are to determine and compare DNA damage in
patients with schizophrenia and schizoaffective disorder, to assess the
roles of oxidative metabolism and DNA repair mechanisms in this pro-
cess, to assess the contribution of drugs, and thus to demonstrate the
differences between schizophrenia and schizoaffective disorder and to
re-examine schizoaffective disorder, which in the past was evaluated
in the schizophrenia spectrum.2. Method
The present study included 30 patients with schizophrenia and 30
patients with schizoaffective disorder, diagnosed according to the
DSMV, at the Pamukkale UniversityMedical School Department of Psy-
chiatry. Each patient had at least five years of disease history, was aged
between 18 and 60 years, and had no physical or neurological disease.
The control group was composed of 30 healthy volunteers, matched
for age and smoking habits, with normal mental capacities, no physical,
neurological or psychiatric disease, and no medication.
Each participant or their legal representative was informed about
the study, and written informed consent was obtained in accordance
with the Declaration of Helsinki. Prior to the research, approval was re-
ceived from Pamukkale University's Non-Interventional Clinical Investi-
gations Ethics Committee dated 24.04.2015 and numbered 60116787-
020/23917.
A sociodemographic data form was completed, and the SCID-5
(Structured Clinical İnterview for the DSM V) was administered to
each participant (Kocabas et al., 2018). The PANSS (Positive and
Negative Syndrome Scale) (Kostakoglu et al., 1999) and CGI (Clini-
cal Global Impression) (Guy, 2000) were also administered to the
patients with schizophrenia, and the PANSS, CGI, HAM-D (Hamil-
ton Depression Rating Scale) (Akdemir et al., 2001) and YMRS
(Young Mania Rating Scale) (Karadag et al., 2002) were adminis-
tered to the patients with schizoaffective disorder. Patients were
selected from among referral, walk-in clinic and inpatients to eval-
uate the relationship between the severity of the disease and DNA
damage.
A total of 5 ml of venous blood was obtained from each partici-
pant for analysis. DNA damage was measured in lymphocytes via
the comet assay method; TAS (total antioxidant status), TOS (total
oxidant status) and OSI (oxidative stress index) measurements
were obtained by ELISA; and OGG1 (8-oxoguanine DNA glycosylase)
and NEIL1 (Nei-like DNA glycosylase) gene expression levels were
obtained by real-time PCR. Additionally, the DNA-damaging effects
of drugs commonly used by the patients were analyzed by the
in vitro assay method of the blood samples obtained from the
healthy volunteers in our study. Blood samples were analyzed im-
mediately after being received and were studied in the dark so that
the samples were minimally affected by environmental factors.
Moreover, to minimize the effects of diet, fasting blood samples
were obtained.2.1. Comet assay
The comet assaywas used to determine DNA damage and genotoxic
situations of control in lymphocyte cells of patients with schizophrenia
and patients with schizoaffective disorder. Lymphocytes were isolated
by using histopaq (Histopaque, Sigma) with Leucosep™ Centrifuge
Tubes. The cells were suspended in 0.1 M PBS (20,000 cells in 25 μl
PBS). Three frosted slides per sample were prepared by adding three
layers of low-melting point agarose gel (LMPA, 37 °C). The first layer
consisted of 1.8% LMPA. A second layer of 25 μl of cell suspension and
175 μl of 1% LMPA was added to the solidified first layer. A third layer
consisting of 1% LMPA (200 μl)was subsequently added. Once solidified,
all slides were immersed in freshly prepared cold lysing solution [2.5 M
NaCl, 100 mM EDTA, 1% Triton X-100, 10 mM Tris (pH 10) and 10%
DMSO] and incubated (1 h., 4 °C). Following incubation, the slides
were placed in an electrophoresis buffer [0,3 M NaOH, 1 mMNa2EDTA;
pH 13] for 20 min at 4 °C. The slides were then electrophoresed (25 V
(300 mA, approx. 0.74 V/cm)) for 35 min at 4 °C. Then, the slides were
washed three times with a neutralization buffer [0.4 M Tris; pH 7.5]
for 5 min each. After this step, the slides were plunged into methanol
for 5 min at−20 °C for fixation of the cells to the slides. After that, the
slides were placed on a smooth surface and dried. Slides were stained
with ethidium bromide (40 μl) prior to observation. Slides were viewed
using aNikonfluorescencemicroscopewith 510–560 nmexcitation and
590 nm emission filters. Images of at least 50 randomly selected comets
on each triplicate slide were captured per sample at 20×magnification,
and image analyses were performed using the comet assay IV Version
4.3.2 for Basler FireWire and are reported in μm.
Broken DNA molecules migrate at different rates in electrical fields,
as they have different molecular weights and electric charges. The dam-
aged pieces of DNA moving towards an anode present a comet-like
image, but undamaged DNA cannot come out of the helical structure
(Green et al., 1996; McKelvey-Martin et al., 1993). The parameters
used to evaluate damage were the HL (head length, μm), TL (tail length,
μm)HD (head density: percentage of DNA in the head), TD (tail density:
percentage of DNA in the tail), and TMo (tail moment: expressed in μm,
the value obtained by dividing the product of TL and TD by 100). As DNA
damage increases, the head length increases, head density decreases;
and the tail length, tail density, and tail moment increase (Fig. 1).
2.2. In vitro assay
An in vitro analysis was carried out to assesswhether the drugs used
by the patients could induce DNA damage. Valproic acid, olanzapine,
clozapine, risperidone, quetiapine, paliperidone, amisulpride, and
biperiden were the drugs most frequently used. In this scope, approxi-
mately 3 ml of blood was taken for each sample from three healthy vol-
unteers selected from the control group, and one of these blood samples
was used as a negative control without any drugs being present. Thus,
DNAdamagewas evaluated in three different blood samples for reliabil-
ity of the test results. The drugs were diluted in water at 0.1–0.5% of the
therapeutic levels and incubated with peripheral blood (provided by
healthy volunteers) for 30 min at 37 °C (Andreazza et al., 2007; Ucok
and Soygur, 2010). After a period of incubation, DNA damage was eval-
uated using the comet procedure, as previously described. The selected
doses were 1000 mg of valproic acid, 20 mg of olanzapine, 400 mg of
clozapine, 6 mg of risperidone, 800 mg of quetiapine, 9 mg of
paliperidone, 800 mg of amisulpride, and 4 mg of biperiden.
2.3. Measurement of TAS, TOS and OSİ
First, serum samples were obtained by centrifugation from blood
samples taken from the control group and the patient groups. Samples
were obtained with a Rel ASSAY Diagnostics Kit (Turkey). There were
three chemicals in the kit, namely, buffer (reagent 1), prochromogen
(reagent 2), and standard (reagent 3). Before starting the study, the
Fig. 1. Comet Images: Images of increasing DNA damage.
Table 2
Sociodemographic characteristics of groups.
Schizophrenia
n (%)
Schizoaffective
n (%)
Control
n (%)
p
Age mean (ss) 39.43 ± 7.81 35.56 ± 9.78 36.66 ± 6.80 0.178a
Gender
Female 9 (30.0) 16 (53.3) 17 (56.7) 0.079b
Male 21 (70.0) 14 (46.7) 13 (43.3)
Cigarette
Yes 16 (53.3) 17 (56.7) 14 (46.7) 0.745b
No 13 (43.3) 12 (40.0) 13 (43.3)
Quit 1 (3.3) 1 (3.3) 3 (10.0)
Alcohol
No 28 (93.3) 26 (86.7) 21 (30.0) 0.060b
Rarely 2 (6.7) 4 (13.3) 6 (20.0)
1–2 per week 0 (0.0) 0 (0.0) 3 (10.0)
BMI mean (ss) 28.16 ± 4.46 27.09 ± 4.03 28.21 ± 5.46 0.685c
Duration of illness
b
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the kit protocol. The samples were analyzed in duplicate and were
read at the 660-nmwavelength with the aid of an Eliza reader (BioTek)
and were calculated by a formula according to the manufacturer's in-
structions. Thereby, the TAS (total antioxidant status) and TOS (total ox-
idant status) values were measured.
OSIwas calculated by the formulaOSI=TOS/TAS* 1/10, according to
the kit instructions.
2.4. RNA isolation and real-time PCR
Total RNA was isolated from the lymphocyte cells using TRIzol Re-
agent (İnvitrogen, USA) according to manufacturer's instructions.
cDNA synthesis from the RNA templatewas performed via reverse tran-
scription by using a Transcriptor First-Strand cDNA Synthesis Kit
(Roche, Germany) according to the manufacturer's protocols. OGG1
and NEIL 1 gene expression analyses were performed by Step One Plus
Real-Time RT-PCR (Applied Biosystems, USA) according to the SYBR
Green qPCR Master Mix (Thermo Scientific, USA) protocol. The RT-PCR
assay was performed using gene-specific primers. The expression re-
sults were normalized to the beta-actin gene (housekeeping gene) ex-
pression levels to calculate the relative expression ratios. The primer
sequences used in this study are given in Table 1.
2.5. Statistical analysis
Statistical analyseswere performed by using SPSS 17.0 forWindows.
Continuous variables are shown as the mean, standard deviation, me-
dian, and interquartile ranges. Categorical variables are shown as the
number and percentage. Comparisons of independent groupswere con-
ducted. Independent-samples t-tests and one-way ANOVA were used
when the parametric test assumptions were satisfied, and when the
parametric test assumptions were not satisfied, the Mann-Whitney U
test and the Kruskal-Wallis analysis of variance were used. Chi-square
analysis was used to compare categorical variables. Pearson correla-
tional analyses were used to evaluate the relationships between contin-
uous variables. The Bonferroni correctionwas performed to avoid type 1
errors, and the level of significance was determined by dividing the p-
value (0.05) into the number of pairwise comparisons. Linear regression
analyses (Backward) were performed to detect independent factors af-
fecting DNA damage. The level of (p) 0.05was used to determine statis-
tical significance. All gene expression analyses of the findings were
performed according to the delta-delta CT method and were quanti-
tated with a computer program. The comparison of the groups wasTable 1
Primer sequences of the genes used in this study.
Name Primer sequence
1 Beta-actin F:TCCTCCTGAGCGCAAGTACTC
R:CTGCTTGCTGATCCACATCTG
2 OGG1 F:CTGATGGCCCTAGACAAGCC
R: ACTGAACAGCACCGCTTGG
3 NEİL1 F:GCAGTGGGAAGTCAGGTTCT
R:GGCCTCATTCACAAACTGGperformed with “RT2 Profiles PCR Array data analysis,” which is
assessed statistically using the “Student t-test”.
3. Results
The sociodemographic characteristics of the groups are presented in
Table 2. There were no statistically significant differences between the
groups in terms of age, gender, alcohol and smoking habits or body
mass index (BMI). The patients with schizophrenia were found to
have longer durations of illness and were living in rural areas (Table 2).
The results of the comet analysis were compared according to the
head length (HL), tail length (TL), head density (HD), tail density
(TD), and tail moment (TM) parameters, and the findings are presented
in Table 3. The head lengths and tail lengths were found to be higher in
thepatientswith schizophrenia than in thepatientswith schizoaffective
disorder and control patients (Table 3). No significant differences were
found in any of the parameters between the schizoaffective and control
groups (Table 3).
The analysis of the relationships between the sociodemographic
data and DNA damage showed that DNA damage was higher in the
male group than in the female group (TL p = 0.004, TM p = 0.006).
No significant relationshipwas observed between age and DNA damage
(Table 4). Although there was an incremental increase in the extent of
DNA damage in smokers, this change was not statistically significant
(Table 4). However, there was a relationship between DNA damage
and the number of cigarettes used; it was observed that DNA damage5–10 years 12 (40.0) 22 (73.3) – 0.029
10–20 years 14 (46.7) 7 (23.3) –
N20 years 4 (13.3) 1 (3.3) –
Living
Urban 19 (63.3) 27 (90.0) 28 (93.3) 0.004b
Rural 11 (36.7) 3 (10.0) 2 (6.7)
Working status
Employed 7 (23.3) 8 (26.7) 28 (93.3) 0.000b
Unemployed 23 (76.7) 22 (73.3) 2 (6.7)
a One Way ANOVA Test.
b Chi-square Test.
c Kruskal Wallis.
Table 3
Comparison of groups' comet values.
Schizophrenia
n (%)
Schizoaffective
n(%)
Control
n(%)
pa
Head length 84.12 ± 12.73 68.71 ± 17.73 72.16 ± 11.91 b0.001
Tail length 86.90 ± 32.58 67.51 ± 35.39 73.59 ± 22.73 0.008
Head density 77.13 ± 13.60 77.64 ± 12.12 78.13 ± 14.72 0.819
Tail density 22.86 ± 13.60 22.30 ± 12.11 21.77 ± 14.68 0.807
Tail moment 11.57 ± 10.65 9.90 ± 13.24 11.10 ± 9.28 0.407
a Kruskal Wallis Test (The difference in head length and tail length is due to the
schizophrenia group.)
Table 5
Medications of the groups.
Schizophrenia
% (n)
Schizoaffective
% (n)
Pa
Biperiden 30.0 (9) 26.7 (8) 1.000
Olanzapine 40.0 (12) 53.3 (16) 0.438
Amisulpirid 36.7 (11) 36.7 (11) 1.000
Risperidone 30.0 (9) 20.0 (6) 0.551
Valproic acid 10.0 (3) 66.7 (20) b0.001
Quetiapine 30.0 (9) 63.3 (19) 0.020
Paliperidone 23.3 (7) 53.3 (16) 0.034
Clozapine 3,3 (1) 6.7 (2) 1.000
Bold face is the value that is statistically significant.
a Chi-square Test.
Table 6
Comet values measured before and after in vitro drug exposure.
Biperiden Olanzapine Amisulpirid Risperidone
HLBI 67.77(±3.52) 67.77(±3.52) 67.77(±3.52) 67.77(±3.52)
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a day (HL p = 0.044). There was no significant correlation between
drinking alcohol and DNA damage. BMI was also not correlated with
DNA damage (Table 4). The duration of disease was grouped as follows:
five to 10 years, 10 to 20 years, and over 20 years. No significant corre-
lationwas found between the duration of disease and DNA damage (HL
p = 0.436; TL p = 0.568; HD p = 0.315; TD p = 0.315; and TM p =
0.579). Furthermore, we found no relationship between the severity of
the disease andDNAdamage as a result of the correlational analysis per-
formed with the applied psychometric scales (Table 4).
The medications of the groups are shown in Table 5. The usage rates
of quetiapine, paliperidone and valproic acid were found to be low in
patients with schizophrenia (Table 5). The relationship between
comet values and the use of drugs such as quetiapine, olanzapine, ris-
peridone, clozapine, paliperidone, amisulpride, valproic acid, and
biperiden was also evaluated in the sample. We did not find any signif-
icant correlations between the use of drugs and head density, tail den-
sity or tail moment (p N 0.05). However, head lengths were found to
be significantly lower in patients using paliperidone (p = 0.037) and
in patients using clozapine (p= 0.017) than in the other patients. Sim-
ilarly, in patients using valproic acid, both head length (p= 0.021) and
tail length (p = 0.046) were significantly low. These results showed us
that DNA damage is less severe in patients using clozapine,
paliperidone, and valproic acid.Table 4
Relationships between data and DNA damage.
Head length Tail length Head density Tail density Tail moment
Age r 0.143 0.076 0.196 0.197 0.189
Pa 0.179 0.478 0.065 0.062 0.075
Gender Pb 0.777 0.004 0.054 0.054 0.006
Smoke Pc 0.242 0.274 0.422 0.419 0.407
Alcohol Pc 0.393 0.296 0.204 0.235 0.252
BMI r 0.181 0.133 0.022 0.019 0.040
Pa 0.087 0.210 0.841 0.858 0.711
PANSS r 0.196 0.042 0.055 0.053 0.109
Pa 0.196 0.750 0.675 0.690 0.407
HAM-D r 0.059 0.105 0.012 0.012 0.106
Pa 0.654 0.429 0.928 0.931 0.423
YMRS r 0.089 0.053 0.007 0.008 0.156
Pa 0.504 0.688 0.956 0.955 0.237
CGI r 0.178 0.122 0.171 0.170 0.152
pa 0.174 0.353 0.191 0.194 0.247
TAS r 0.009 0.015 0.119 0.121 0.059
Pa 0.930 0.889 0.266 0.258 0.580
TOS r 0.059 0.093 0.135 0.134 0.118
Pa 0.580 0.383 0.204 0.209 0.268
OSI r 0.047 0.082 0.114 0.113 0.092
Pa 0.662 0.444 0.283 0.288 0.391
OGG-1 r −0.264 −0.258 0.027 0.027 0.124
Pa 0.012 0.014 0.798 0.799 0.244
NEIL-1 r 0.031 0.052 0.054 0.056 0.065
Pa 0.770 0.627 0.614 0.601 0.543
Bold face is the value that is statistically significant.
a Pearson Correlation Analysis.
b Mann Whitney Test.
c Kruskal Wallis Test.Measurementsmade through in vitro analyses before and after drug
exposure showed that thesemedicines did not induce any DNAdamage
in the lymphocytes (Table 6).
Through analyses of the oxidative process in the schizoaffective dis-
order group, the TOS was measured as 2.96 (±3.22), and OSI was 0.26
(±0.32); in the schizophrenia group, the TOS was 6.95 (±5.34), and
OSI was 0.48 (±0.49); and in the control group, the TOS was 9.73 (±
1.94), and OSI was 0.95 (±0.44). The TOS and OSI values were found
to be significantly lower in the patients with schizoaffective disorder
than in the patients with schizophrenia (Table 7). In addition, the rela-
tionship between the oxidative processes and DNA damage was inves-
tigated by correlational analyses between comet values and the TAS,
TOS and OSI values; and there was no significant relationship between
DNA damage and the oxidative processes (Table 4).
OGG1 and NEIL 1 gene expression levels were examined in terms of
DNA repair mechanisms. OGG1 gene expression fold changes wereHLAI 70.51(±4.47) 68.26(±2.22) 65.36(±2.11) 60.38(±3.68)
pa 0.109 1.00 0.285 0.109
TLBI 53.28(±9.60) 53.28(±9.60) 53.28(±9.60) 53.28(±9.60)
TLAI 59.75(±4.15) 60.57(±5.99) 51.87(±17.26) 56.95(±16.8)
pa 0.285 0.285 1.00 0.593
HDBI 85.84(±1.56) 85.84(±1.56) 85.84(±1.56) 85.84(±1.56)
HDAI 83.33 84.26(±5.59) 83,90(±8.63) 83.27(±8.53)
pa 0.285 0.593 0.593 1.00
TDBI 14.15(±1.56) 14.15(±1.56) 14.15(±1.56) 14.15(±1.56)
TDAI 16.66(±4.47) 15.73(±5.59) 16.09(±8.63) 16.72(±8.53)
pa 0.285 0.593 0.593 1.00
TMBI 5.50(±1.43) 5.50(±1.43) 5.50(±1.43) 5.50(±1.43)
TMAI 6.96(±1.81) 9.75(±6.00) 9.17(±8.03) 8.83(±7.28)
pa 0.109 0.285 0.593 0.593
Valproicacid Quetiapine Paliperidone Clozapine
HLBI 67.77(±3.52) 67.77(±3.52) 67.77(±3.52) 67.77(±3.52)
HLAI 66.67(±3.39) 70.6(±3.80) 71.80(±3.87) 74.78(±2.60)
pa 0.109 0.109 0.109 0.109
TLBI 53.28(±9.60) 53.28(±9.60) 53.28(±9.60) 53.28(±9.60)
TLAI 63.84(±12.68) 65.33(±16.6) 65.34(±0.46) 73.34(±4.60)
pa 0.109 0.285 0.109 0.109
HDBI 85.84(±1.56) 85.84(±1.56) 85.84(±1.56) 85.84(±1.56)
HDAI 80.43(±1.79) 81.36(±4.63) 82.89(±3.10) 83.90(±3.17)
pa 0.109 0.109 0.109 0.593
TDBI 14.15(±1.56) 14.15(±1.56) 14.15(±1.56) 14.15(±1.56)
TDAI 19.56(±1.79) 18.63(±4.63) 17.11(±3.10) 15.23(±4.04)
pa 0.109 0.109 0.109 1.00
TMBI 5.50(±1.43) 5.50(±1.43) 5.50(±1.43) 5.50(±1.43)
TMAI 7.58(±0.98) 9.35(±3.58) 9.49(±5.02) 6.83(±2.09)
pa 0.109 0.109 0.109 1.00
a Wilcoxon Paired Two Sample Tests HLBI(Head Length Before İncubation), HLAI(Head
Length After İncubation), TLBI (Tail Length Before Incubation), TLAI(Tail Length After İncu-
bation), HDBI(Head Density Before Incubation), HDAI(Head Density After Incubation)
TDBI(Tail Density Before Incubation), TDAI(Tail Density After Incubation), TMBI (Tail Mo-
ment Before Incubation), TMAI (Tail Moment After Incubation).
Table 7
Comparison of oxidative metabolism values of patients with schizophrenia and
schizoaffective disorder.
Schizophrenia Schizoaffective pa
TOS 6.95 ± 5.34 2.96 ± 3.22 0.001
TAS 1.74 ± 0.47 1.59 ± 0.42 0.222
OSİ 0.48 ± 0.49 0.26 ± 0.32 0.016
Bold face is the value that is statistically significant.
a MannWhitney Test TOS (Total oxidant status), TAS (total antioxidant status), OSI
(Oxidative stress index).
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in the schizoaffective disorder group, and 27.20 (±2.90) in the control
group. NEIL 1 gene expression fold changes were measured as 33.60
(±4.01) in the schizophrenia group, 34.77 (±2.17) in the
schizoaffective disorder group, and 34.35 (±2.26) in the control
group. OGG1 gene expression fold changes were significantly higher
in the schizoaffective disorder group than in both the schizophrenia
and control groups (p b 0.001) (Fig. 2). In addition, the relationship be-
tween DNA damage and repairmechanismswas investigated using cor-
relational analyses between comet values and OGG1 and NEIL 1 gene
expression levels. A negative correlation was found between OGG1
gene expression levels and DNA damage. There was no significant rela-
tionship with the NEIL1 values (Table 4).
Linear regression analysis (backward) was performed to detect in-
dependent factors affectingDNAdamage, including themodel age; gen-
der; number of cigarettes smoked; BMI; level of OGG1; and use of
paliperidone, valproic acid and clozapine. The use of clozapine was
found to be an independent factor affecting head length (B = 24.97,
standard error = 10.15, beta = 0.344, p = 0.020). OGG1 gene expres-
sion level was also found to be an independent factor affecting tail
length (B = −3.79, standard error 1.81, beta = −0.352, p = 0.044).
4. Discussion
The most important finding in this study was that patients with
schizophrenia had significantly greater DNA damage than the patients
with schizoaffective disorder and the controls. This study also provided
evidence of high oxidative stress statuses and inadequate DNA repair
capacities in patients with schizophrenia. Moreover, psychotropic
drugs did not induce any DNA damage in the lymphocytes.
Many studies have shown DNA damage in schizophrenia
(Muraleedharan et al., 2015; Psimadas et al., 2004). Studies of oxidative
metabolism have been previously performed in schizoaffective disorder
patients (Bulbul et al., 2014). However, despite searching in the litera-
ture, we did not come across any study of DNA damage that used the
comet assay method. Single-cell gel electrophoresis (comet assay),
used also in humans, is a sensitive method for detecting major DNAFig. 2. OGG1 and NEIL1 gen exprdamage (Tice et al., 2000). In our study, we found that the DNA damage
in the schizophrenia group was higher than that in the schizoaffective
disorder and control groups. To the best of our knowledge, our study
is the first to evaluate DNA damage measured by the comet method
with repairmechanisms, oxidative processes, and drug effects in schizo-
phrenia and schizoaffective disorder patients.
The results of studies reporting the relationship between sex
and genotoxicity have been contradictory (Moller et al., 2000;
Muraleedharan et al., 2015). In our study, the detection of higher
DNA damage in men than in women might be associated with the
different smoking statuses of the male and female patients. Al-
though there are conflicting studies, it is known that there is a rela-
tionship between aging and DNA damage (Jorgensen et al., 2013;
Soares et al., 2014). We, however, did not find any correlation be-
tween age and DNA damage.
Studies have shown that free radicals in cigarettes induce DNA dam-
age in smokers (Pryor et al., 1998) and effects on comet parameters
(Moller et al., 2000). In our study, although the numbers showed
more damage in smokers, we did not find any significant correlation be-
tween smoking and genotoxicity. In our interpretation, this findingwas
probably due to the small sample size since DNA damage was found to
increase significantly as the number of cigarettes used increased.
Alcohol is known to cause oxidative DNA base modifications and
breaks via the production of hydroxyacetyl free radicals during ethanol
metabolism (Clot et al., 1994). There have been reports that this DNA
damage is also related to frequent drinking (Weng et al., 2010). On
the other hand, Horak et al. (2003) and Gaspari et al. (2003) claimed
that there is no relationship between alcohol and DNA damage, and
no relationship was found between alcohol use and DNA damage in
this study. Additionally, DNA damage was not related to the duration
of illness or the severity of symptoms, findings that were consistent
with the literature (Andreazza et al., 2007; Muraleedharan et al., 2015).
Although there are conflicting results, studies have suggested that
lower or higher BMIs are possibly associated with DNA damage (Dick
et al., 2014; Mizoue et al., 2007). We found no relationship between
BMI and DNA damage. However, eating problems and long-term
changes in BMI are common both in schizophrenia and schizoaffective
disorder due to disease characteristics and medications; therefore, lon-
gitudinal studies are needed.
As Muraleedharan et al. (2015) indicated, significant baseline DNA
damage in schizophrenia is present even prior to the initiation of anti-
psychotic treatment. Additionally, intact genomic repair efficiency was
noted in patients diagnosed with first episodes of schizophrenia, and
it was observed that a longer duration of untreated illness decreased re-
pair capacity. However, some previous studies have shown the influ-
ence of antipsychotics on DNA damage. For example, subchronic
treatment of aripiprazole has been shown to cause DNA damage in the
peripheral blood of rats (Picada et al., 2011). In another animal study,ession levels of the groups.
104 O.Z. Topak et al. / Schizophrenia Research 202 (2018) 99–105Reinke et al. (2004) reported an increased level of lipid peroxidation
product (thiobarbituric acid) with haloperidol but not with clozapine,
and protein carbonyls increased with both haloperidol and clozapine.
On theother hand, the researchers observed no increase in oxidative pa-
rameters with olanzapine. Parikh et al. (2003) found that chronic use of
haloperidol causes oxidative stress and membrane lipid peroxidation
but not olanzapine, risperidone, or clozapine use. In another in vitro
study performed using lymphocyte cultures, olanzapine was found to
cause damage only in high doses (Turkez and Togar, 2010). Psimadas
et al. (2004) did not find any association of DNA damage or repair effi-
ciency with Aloperidin, Nozinan, or Risperdal in human lymphocytes.
Moreover, Tsai et al. (2013) found an incremental increase in antioxi-
dant enzyme activity and glutathione peroxidase after four weeks of
paliperidone treatment. Wakade et al. (2002) found an increase in
bromodeoxyuridine, used to define newly divided cells, in rats that
had been treated with atypical antipsychotics as distinct from typical
antipsychotics; and demonstrated the stimulation of neurogenesis and
neuronal repairwith the use of atypical antipsychotics. All of these stud-
ies indicated to us that atypical antipsychotics cause less oxidative dam-
age than typical antipsychotics. In our study, the use of quetiapine,
olanzapine, risperidone, amisulpride, paliperidone, or clozapine did
not increase DNA damage; in fact, DNA damage was significantly low
in patients using clozapine and paliperidone, which was consistent
with the literature. In the present study, the effects of drugs on DNA
damage were also checked by the in vitro assay method, and consistent
with the literature (Andreazza et al., 2007; Psimadas et al., 2004), our
findings showed that these drugs did not induce any DNA damage to
the lymphocytes.
The antioxidant and neuroprotective features of mood stabilizers
have been demonstrated in animal and cell-based studies. For example,
in animals with amphetamine-induced mania, it has been shown that
lithium and valproate inhibit lipid peroxidation in the hippocampus
and the prefrontal cortex (Frey et al., 2006). Similarly, lithium and
valproate have been shown to prevent new DNA damage by modifying
the oxidative balance (Andreazza et al., 2008). Furthermore, Tokarz
et al. (2016) showed that, in chronic oxidative stress conditions,
valproic acid reduces intracellular reactive oxygen species and damage
to DNA. In another study, valproic acid was shown to enhance the anti-
tumor effects of topoisomerase 2 inhibitors in mice with tumors
(Marchion et al., 2005). Our results showed a significantly low level of
DNA damage in patients using valproic acid, as found in the literature.
Compared to other tissues of the body, the central nervous system,
with its high oxygen consumption and lipid-rich environment, is con-
sidered highly susceptible to oxidative stress and redox imbalances
(Salim, 2014). Therefore, the fact that oxidative stress is implicated in
several mental disorders, including schizophrenia, is not surprising. Al-
beit with conflicting results, oxidative stress is thought to play a role in
the pathophysiology of schizophrenia (Dadheech et al., 2008; Wood
et al., 2009). İnformation about the relationship between oxidative
stress and schizoaffective disorder is limited in the literature. Bulbul
et al. (2014) showed that oxidative stress was higher in patients with
schizoaffective disorder than in patients with schizophrenia and bipolar
disorder. However, in our study, the TOS and OSI values in the
schizoaffective disorder group were significantly lower than those in
the schizophrenia group. Oxidative stress levels are affected by many
parameters, such as duration of illness, age, gender, smoking habits, nu-
trition habits, lifestyle, exercise, and BMI (Boskovic et al., 2011; Tuncel
et al., 2015; Ustundag et al., 2006). Therefore, we regard this as a con-
flicting result. Moreover, in our study, we did not find any relationship
between comet values and TAS, TOS or OSI values. This suggested that
simply evaluating the oxidative processes in the formation of DNA dam-
age would not be adequate, andmore sensitivemethods, such as comet
assays, are required. In fact, in an animal study, Jorgensen (2013)
showed a tendency for the genes involved in DNA repair to increase
without an increase in urinary 8-oxo-7,8-dihydroguanosine levels, a
product of nucleic acid oxidation and marker for chronic stress.Polymorphisms in genes involved in DNA repair, such as OGG1 and
NEIL1, can change the function and activity of proteins and the repair
capacity of individuals. An inadequate repair capacity is an important
contributing factor to genetic instability (Ekmekci et al., 2008). The
OGG1 gene expression level and the use of clozapine were found to be
independent factors in the present study. In other words, the use of clo-
zapine and adequate repair processes of the patients were more deci-
sive factors in the prevention of DNA damage.
Some limitations of the present study should be taken into consider-
ation. It is known that patients with schizophrenia and schizoaffective
disorder use multiple drugs during their illness. Less frequently used
classes of drugs were not evaluated in the present study. Furthermore,
limiting the drug selection to the last four weeks of treatment and the
lack of scale to evaluate drug compliance are the other limitations of
our study. Additionally, we cannot disregard the influence of nutritional
habits, lifestyle, exercise, and other nonspecific factors on DNA damage.
Thus, the lack of amechanism formeasuring such genotoxic variables is
another limitation of this study. Further studies will help clarify this
issue.
To conclude, the results of this study provide a reexamination of
schizoaffective disorder within the schizophrenia spectrum and indi-
cate that schizoaffective disorder may be differentiated from schizo-
phrenia and may be considered a different diagnostic category.
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